Biological Imaging Reagents Segmentation
Application (Clinical diagnostics, Drug discovery and development, Research and innovation, Other applications)
Clinical diagnostics segment in the biological imaging reagents market is purported to be the largest segment with a lucrative share of 42.3% as advanced diagnostic tools for early and accurate detection of diseases increase the demand. Imaging reagents are contrast agents used in MRI and CT scans or radiopharmaceuticals in PET scans. For instance, The FDA published a report in March 2024 stating the fact as of July 2023, that 692 AI-enabled medical devices had been approved for sale out of which 75% are used in the radiology field.
Imaging Modality (MRI, Ultrasound, X-ray and CT, Optical imaging, Nuclear imaging)
Advanced optical imaging tools such as sensitivity and resolution improvement continue to enhance optical imaging's usefulness in both research and clinical applications. Ongoing technological development along with expanding applications into drug discovery, disease diagnosis, and therapeutic monitoring are expected to trend the optical imaging segment further. The researchers seek novel solutions to monitor biological activities in real time. For example, GE HealthCare announced in November 2023 the launch of MyBreastAI suite, a platform of AI apps that helps with imaging workflows and breast cancer detection.
Our in-depth analysis of the biological imaging reagents market includes the following segments:
|
Product Type |
|
|
Imaging Modality |
|
|
End user |
|
|
Application |
|
